C4 Therapeutics shares cemsidomide biomarker data at myeloma meeting

September 25, 2026 7:00 AM

C4 Therapeutics, Inc. (Nasdaq: CCCC) presented new biomarker data from two clinical trials of cemsidomide in relapsed/refractory multiple myeloma at ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found